Tscan Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Tscan Therapeutics
TCRX Stock  USD 1.72  0.09  5.52%   
Tscan Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Tscan Therapeutics' valuation are provided below:
Gross Profit
-2 M
Market Capitalization
97.3 M
Enterprise Value Revenue
7.6417
Revenue
2.8 M
Earnings Share
(1.14)
We have found one hundred twenty available fundamental trend indicators for Tscan Therapeutics, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Tscan Therapeutics current market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. Enterprise Value is likely to rise to about 238.4 M in 2025, whereas Market Cap is likely to drop slightly above 173.6 M in 2025.

Tscan Therapeutics Total Revenue

2.68 Million

Check Tscan Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tscan Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 8.8 M, Interest Income of 12.7 M or Depreciation And Amortization of 3.6 M, as well as many indicators such as Price To Sales Ratio of 86.63, Dividend Yield of 0.0 or PTB Ratio of 1.48. Tscan financial statements analysis is a perfect complement when working with Tscan Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Tscan Stock
Check out the analysis of Tscan Therapeutics Correlation against competitors.
For more information on how to buy Tscan Stock please use our How to Invest in Tscan Therapeutics guide.

Tscan Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets207.1 M371.1 M111.3 M
Slightly volatile
Short and Long Term Debt Total48 M65.3 M22.1 M
Slightly volatile
Other Current Liabilities16.2 M15.4 M3.9 M
Slightly volatile
Total Current Liabilities22.8 M36 M10.5 M
Slightly volatile
Property Plant And Equipment Net45.5 M71.6 M22 M
Slightly volatile
Current Deferred Revenue8.9 M11.7 M4.1 M
Slightly volatile
Accounts Payable2.8 M4.3 M1.7 M
Slightly volatile
Cash122.8 M178.7 M73 M
Slightly volatile
Non Current Assets Total51 M78.4 M24.5 M
Slightly volatile
Non Currrent Assets Other4.6 M6.8 M2.2 M
Slightly volatile
Other Assets3.4 M6.6 M2.1 M
Slightly volatile
Cash And Short Term Investments154 M290.1 M85.6 M
Slightly volatile
Common Stock Total Equity2.6 K2.7 K19.7 K
Slightly volatile
Common Stock Shares Outstanding117.6 M112 M38.6 M
Slightly volatile
Liabilities And Stockholders Equity207.1 M371.1 M111.3 M
Slightly volatile
Non Current Liabilities Total75.7 M94.2 M66.6 M
Pretty Stable
Capital Lease Obligations37.2 M65.3 M17.7 M
Slightly volatile
Other Current Assets3.6 M2.6 M1.8 M
Slightly volatile
Total Liabilities98.5 M130.1 M77.1 M
Slightly volatile
Property Plant And Equipment Gross94.8 M90.3 M23.1 M
Slightly volatile
Total Current Assets156.1 M292.7 M86.8 M
Slightly volatile
Net Working Capital134.1 M256.8 M76.6 M
Slightly volatile
Short Term Debt4.3 M4.6 M2 M
Slightly volatile
Property Plant Equipment11.2 M11.6 M8.2 M
Slightly volatile
Other Liabilities41.9 K44.1 K6.3 M
Slightly volatile
Non Current Liabilities Other103.8 K121.5 K195.3 K
Slightly volatile
Common Stock3.7 K5.8 K2 K
Slightly volatile
Capital Surpluse280.9 M296.5 M258 M
Slightly volatile
Long Term Debt32.3 M32.1 M29.5 M
Slightly volatile
Short and Long Term Debt2.7 M3 M3.3 M
Slightly volatile

Tscan Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Interest Income8.8 M8.4 M1.6 M
Slightly volatile
Interest Income12.7 M12.1 M2.4 M
Slightly volatile
Depreciation And Amortization3.6 M4.1 M1.7 M
Slightly volatile
Selling General Administrative18.8 M30.3 M10.3 M
Slightly volatile
Other Operating Expenses79.3 M137.6 M40 M
Slightly volatile
Research Development60.6 M107.3 M29.7 M
Slightly volatile
Cost Of Revenue106.4 M101.4 M20.6 M
Slightly volatile
Total Operating Expenses79.3 M137.6 M40 M
Slightly volatile
Reconciled Depreciation3.6 M4.1 M1.8 M
Slightly volatile
Total Other Income Expense Net7.7 M7.3 M1.6 M
Slightly volatile
Non Operating Income Net Other332 K373.5 K407.2 K
Slightly volatile
Selling And Marketing Expenses4.3 M4.8 M5.3 M
Slightly volatile

Tscan Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings23.4 M26.1 M28.7 M
Slightly volatile
Stock Based Compensation10 M9.5 M2.2 M
Slightly volatile
Begin Period Cash Flow97 M138.4 M51.1 M
Slightly volatile
Depreciation3.6 M4.1 M1.7 M
Slightly volatile
Capital Expenditures4.9 M3.8 M2.7 M
Slightly volatile
Issuance Of Capital Stock53.3 M33.1 M47.9 M
Pretty Stable
Total Cash From Financing Activities109.7 M208.8 M63.8 M
Slightly volatile
End Period Cash Flow126.7 M183.7 M75 M
Slightly volatile
Change To Netincome5.5 M5.2 M1.6 M
Slightly volatile
Change To Liabilities1.1 M1.1 M1.9 M
Pretty Stable
Sale Purchase Of Stock278.7 K293.4 K142.3 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio86.63121181
Slightly volatile
Stock Based Compensation To Revenue3.563.3910.8127
Slightly volatile
Capex To Depreciation0.880.93112.105
Slightly volatile
Payables Turnover35.0933.427.5939
Slightly volatile
Sales General And Administrative To Revenue11.2910.75535.9067
Very volatile
Research And Ddevelopement To Revenue40.0338.121418.7379
Pretty Stable
Capex To Revenue1.471.35832.9523
Slightly volatile
Cash Per Share2.712.59052.382
Slightly volatile
Days Payables Outstanding10.7411.3474
Slightly volatile
Income Quality0.620.86920.8416
Slightly volatile
Net Debt To EBITDA1.690.94692.1985
Slightly volatile
Current Ratio9.018.141113.5828
Slightly volatile
Capex Per Share0.03240.03420.086
Pretty Stable
Revenue Per Share0.02390.02510.1147
Slightly volatile
Interest Debt Per Share0.860.61580.5673
Slightly volatile
Debt To Assets0.160.1760.1424
Slightly volatile
Days Of Payables Outstanding10.7411.3474
Slightly volatile
Ebt Per Ebit1.080.94570.9738
Slightly volatile
Long Term Debt To Capitalization0.320.20130.4721
Slightly volatile
Quick Ratio9.018.141113.5828
Slightly volatile
Net Income Per E B T0.780.890.9527
Slightly volatile
Cash Ratio7.954.969713.012
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.441.03451.1995
Pretty Stable
Fixed Asset Turnover0.03740.03930.1317
Slightly volatile
Debt Ratio0.160.1760.1424
Slightly volatile
Price Sales Ratio86.63121181
Slightly volatile
Asset Turnover0.00720.00760.0284
Slightly volatile

Tscan Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap173.6 M340.5 M139 M
Slightly volatile

Tscan Fundamental Market Drivers

Cash And Short Term Investments290.1 M

Tscan Upcoming Events

13th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
13th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Tscan Therapeutics Financial Statements

Tscan Therapeutics investors use historical fundamental indicators, such as Tscan Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Tscan Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue11.7 M8.9 M
Total Revenue2.8 M2.7 M
Cost Of Revenue101.4 M106.4 M
Stock Based Compensation To Revenue 3.39  3.56 
Sales General And Administrative To Revenue 10.76  11.29 
Research And Ddevelopement To Revenue 38.12  40.03 
Capex To Revenue 1.36  1.47 
Revenue Per Share 0.03  0.02 
Ebit Per Revenue(47.88)(45.48)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
AMTAmerican Tower Corp
HLTOYHellenic Telecommunications Org
NFLXNetflix

Additional Tools for Tscan Stock Analysis

When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY